Shanghai Shen Lian Biomedical Corp Net Asset Quality Index
Shanghai Shen Lian Biomedical Corp net asset quality index. Shanghai Shen Lian Biomedical Corp (688098) has a Net Asset Quality Index of 91.3% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.53 Billion minus total liabilities of CN¥133.33 Million yields net assets of CN¥1.40 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 688098 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Shanghai Shen Lian Biomedical Corp (2013–2025)
Net asset quality index of Shanghai Shen Lian Biomedical Corp from 2013 to 2025. This chart shows how Shanghai Shen Lian Biomedical Corp's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 91.3%, representing net assets of CN¥1.40 Billion against total assets of CN¥1.53 Billion CNY. See 688098 total equity for net asset value and shareholders' equity analysis.
Shanghai Shen Lian Biomedical Corp Net Asset Quality Index by Year (2013–2025)
Shanghai Shen Lian Biomedical Corp net asset quality index by year from 2013 to 2025. The table below presents the year-by-year Net Asset Quality Index for Shanghai Shen Lian Biomedical Corp from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Shanghai Shen Lian Biomedical Corp market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 90.7% | CN¥1.40 Billion | CN¥1.54 Billion | CN¥143.41 Million | ▼ -1.0 pp |
| 2024 | 91.7% | CN¥1.43 Billion | CN¥1.55 Billion | CN¥128.50 Million | ▼ -2.8 pp |
| 2023 | 94.5% | CN¥1.51 Billion | CN¥1.59 Billion | CN¥86.93 Million | ▲ +1.3 pp |
| 2022 | 93.3% | CN¥1.50 Billion | CN¥1.61 Billion | CN¥108.21 Million | ▲ +1.1 pp |
| 2021 | 92.2% | CN¥1.47 Billion | CN¥1.60 Billion | CN¥125.48 Million | ▼ 0.0 pp |
| 2020 | 92.2% | CN¥1.40 Billion | CN¥1.51 Billion | CN¥118.20 Million | ▲ +3.7 pp |
| 2019 | 88.5% | CN¥1.28 Billion | CN¥1.45 Billion | CN¥166.33 Million | ▲ +6.4 pp |
| 2018 | 82.1% | CN¥831.94 Million | CN¥1.01 Billion | CN¥181.18 Million | ▲ +2.8 pp |
| 2017 | 79.4% | CN¥549.27 Million | CN¥692.19 Million | CN¥142.92 Million | ▲ +2.8 pp |
| 2016 | 76.6% | CN¥465.47 Million | CN¥607.79 Million | CN¥142.32 Million | ▲ +11.8 pp |
| 2015 | 64.7% | CN¥317.41 Million | CN¥490.32 Million | CN¥172.90 Million | ▲ +19.1 pp |
| 2014 | 45.7% | CN¥241.57 Million | CN¥528.89 Million | CN¥287.32 Million | ▼ -16.0 pp |
| 2013 | 61.6% | CN¥327.59 Million | CN¥531.53 Million | CN¥203.94 Million | — |